| __timestamp | Corcept Therapeutics Incorporated | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 882000 | 22732000 |
| Thursday, January 1, 2015 | 1361000 | 29245000 |
| Friday, January 1, 2016 | 2058000 | 33206000 |
| Sunday, January 1, 2017 | 3554000 | 31152000 |
| Monday, January 1, 2018 | 5215000 | 10136000 |
| Tuesday, January 1, 2019 | 5504000 | 45546000 |
| Wednesday, January 1, 2020 | 5582000 | 43367000 |
| Friday, January 1, 2021 | 5281000 | 81413000 |
| Saturday, January 1, 2022 | 5385000 | 139304000 |
| Sunday, January 1, 2023 | 6481000 | 192361000 |
Cracking the code
In the competitive landscape of biotechnology, understanding cost structures is crucial. This analysis delves into the cost of revenue trends for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated from 2014 to 2023. Over this period, Halozyme's cost of revenue surged by an impressive 747%, peaking at $192 million in 2023. This growth reflects their expanding operations and increased production costs. In contrast, Corcept's cost of revenue grew by 635%, reaching $6.5 million in 2023. Despite the smaller scale, Corcept's consistent growth highlights their strategic cost management. Notably, Halozyme's cost of revenue in 2023 was approximately 30 times that of Corcept, underscoring the scale difference between the two companies. These insights provide a window into the financial strategies and operational efficiencies of these biotech firms, offering valuable lessons for investors and industry analysts alike.
Cost Insights: Breaking Down Novartis AG and Halozyme Therapeutics, Inc.'s Expenses
Cost of Revenue Comparison: Gilead Sciences, Inc. vs Corcept Therapeutics Incorporated
Comparing Cost of Revenue Efficiency: Zoetis Inc. vs Corcept Therapeutics Incorporated
Cost of Revenue: Key Insights for BeiGene, Ltd. and Corcept Therapeutics Incorporated
Comparing Cost of Revenue Efficiency: Dr. Reddy's Laboratories Limited vs Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down Jazz Pharmaceuticals plc and Corcept Therapeutics Incorporated's Expenses
Cost of Revenue Trends: Halozyme Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Pharming Group N.V. and Corcept Therapeutics Incorporated's Expenses
Cost of Revenue: Key Insights for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Corcept Therapeutics Incorporated and Celldex Therapeutics, Inc.'s Expenses